4//SEC Filing
Daruwala Paul 4
Accession 0001209191-22-002604
CIK 0001610618other
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 8:26 PM ET
Size
11.8 KB
Accession
0001209191-22-002604
Insider Transaction Report
Form 4
Daruwala Paul
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-12-29+9,900→ 192,431 total - Sale
Common Stock
2022-01-05$1.25/sh−5,133$6,416→ 187,298 total - Exercise/Conversion
Restricted Stock Unit
2021-12-29−5,000→ 12,500 totalExp: 2027-09-17→ Common Stock (5,000 underlying) - Exercise/Conversion
Restricted Stock Unit
2021-12-29−4,900→ 5,600 totalExp: 2029-01-30→ Common Stock (4,900 underlying)
Footnotes (5)
- [F1]The Reporting Person was previously granted restricted stock units to vest upon the achievement of certain milestone events that occurred on December 29, 2021.
- [F2]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on December 29, 2021 and January 1, 2022. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F3]Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer.
- [F4]On September 18, 2017, the Reporting Person was granted restricted stock units totaling 25,000 shares subject to vesting upon the achievement of various milestones.
- [F5]On January 31, 2019, the Reporting Person was granted restricted stock units totaling 14,000 shares subject to vesting upon the achievement of various milestones.
Documents
Issuer
Cidara Therapeutics, Inc.
CIK 0001610618
Entity typeother
Related Parties
1- filerCIK 0001639144
Filing Metadata
- Form type
- 4
- Filed
- Jan 6, 7:00 PM ET
- Accepted
- Jan 7, 8:26 PM ET
- Size
- 11.8 KB